Results 151 to 160 of about 43,624 (266)

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo   +14 more
wiley   +1 more source

Comparative Study of Accommodative Function and Binocular Vision in Patients With Primary Angle‐Closure Disease

open access: yesThe Kaohsiung Journal of Medical Sciences, Volume 42, Issue 5, May 2026.
ABSTRACT The age‐related decline in accommodative function after the age of 50 years corresponds with an increasing incidence of primary angle‐closure disease (PACD); however, the interaction between this decline and PACD remains unexamined. Additionally, refractive error‐accommodation associations in elderly individuals, which are critical for PACD ...
Feng‐Rui Yang   +6 more
wiley   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

open access: yesMedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao   +7 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra   +51 more
wiley   +1 more source

Home - About - Disclaimer - Privacy